found rarely (1, 10) . Nevertheless, vigorous treatment of the predisposing disease is mandatory in secondaryamyloidosis.
In some patients of primary amyloidosis a combination of melphalan and prednisolone has been reported to induce remission of the nephrotic syndrome and stabilization of renal function (11) (12) (13) , yet the only reported controlled trial of such therapy had failed to show an improved survival (14) . Although preliminary results with dimethylsulfoxide, an amyloid fibril denaturing agent have been encouraging (15, 16) , an unpleasant breath odour that may persist up to a week or so after a single dose of the drug is a major problem.
Colchicine, which prevents casein-induced amyloidosis in mice, has been tried in patients with amyloidosis secondary to familial Mediterranean fever (FMF). In most patients with non-nephrotic proteinuria and normal renal function, it has brought about a stabilisation or resolution of proteinuria and prevented deterioration of renal function over a long period of follow up (17) . In patients with uremia or a nephrotic state, however, no improvement was noted.
Hemodialysed patients with end stage renal disease due to amyloidosis have a survival rate 20% less than that of other patients undergoing chronic dialysis (18) . Progressive amyloid infiltration of other organs is often responsible for their limited survival.
Several patients with renal failure due to amyloidosis have undergone renal transplantation (19, 20) . About 10% have had a recurrence of amyloid in the graft, both in AA and AL types. Recurrences usually occur within 36 months of transplantation. Nevertheless, since graft failure is a late complication, transplantation is not contraindicated. The presence of cardiac amyloidosis should be carefully excluded pretransplant since this is associated with poor patient survival. Colchicine should be administered indefinitely to all transplant recipients whose original disease was FMF or primary amyloidosis.
The value of prophylactic colchicine in FMF is well established (17, 21) . Besides preventing attacks of fever and systemic symptoms, it has reduced the prevalence of amyloidosis in FMF to one-third of that before it was introduced. The exact mode of action of colchicine remains uncertain although it is known to inhibit the secretion of SAA protein by hepatocytes. The appearance of amyloidosis is not solely deter-
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mined by SAA levels and colchicine has been found to be of value even in those patients whose attacks of FMF are not helped by it (17) . Amyloidosis in FMF appears to be genetically determined and its development does not correlate with the number, duration, severity, and type of attacks.
Although colchicine may also prove to be useful in preventing amyloidosis secondary to other diseases, the lack of suitable markers which can identify patients at risk for the future development of amyloidosis has prevented its use in these conditions. Since only a small minority of patients with these diseases develop amyloidosis, the routine prophylactic long term use of colchicine in all such patients cannot be recommended at this time. The researchers now,
